

Special Issue

Using Real-World Data for Drug Repurposing and Pharmacovigilance

Message from the Guest Editors

Drug repurposing is the process of identifying new uses for existing drugs or compounds. Pharmacovigilance is the study of the safety of drugs and their potential side effects. Real-world data can be used for both purposes. There are several sources of real-world data, including electronic health records, claims data, and patient registry data. These data sources can provide information about how drugs are being used in real-world clinical practice, as well as any adverse events or side effects that may be associated with their use. Examples, such as research of how statins could be protective for cancer development other than the initial intention of being protective for cardiovascular diseases, or hydroxychloroquine in the treatment of autoimmune disease, such as rheumatoid arthritis, could lead to maculopathy, which could cast an impact on quality of life for poor vision. Nowadays, many drugs are being developed, such as monoclonal antibodies, to tackle cancers and autoimmune diseases, which will make this kind of study more imperative and insightful, as we are all learning from the real-world evidence.

Guest Editors

Dr. Min-Huei Hsu

Dr. Ju-Chuan Yen

Dr. Jason C. Hsu

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/156170

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).